-
but it can't act like a
-
virus any longer because it can't replicate.
-
Then, they did preliminary
-
studies of safety and effectiveness in people.
-
Basically, injecting it into some test subjects,
-
making sure that they didn't get diseased from it
-
and looking at antibody responses to see
-
if it worked and it did.
-
So, very rapidly a clinical trial was started.
-
Now, the problem, or one of the challenges
-
with clinical trials of vaccines
-
is that you have to enroll a lot of patients into clinical trials